Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03600779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Application of ihMT MRI in Multiple Sclerosis

Study acronym: ihMTMS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Feb 13, 2026 → Aug 14, 2027
See other at-risk trials from Assistance Publique Hopitaux De Marseille

Record History

  1. Primary completion pushed from Feb 13, 2026 to Aug 14, 2027 Completion pushed from Feb 13, 2027 to Aug 14, 2028 · Eligibility criteria expanded, about 4 wordsv7 Show 2 more changesShow less
    • Completion pushed from Feb 13, 2027 to Aug 14, 2028
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jun 14, 2024 to Feb 13, 2026 Completion date: Jun 14, 2025 to Feb 13, 2027v6 Show 1 more changeShow less
    • Completion date: Jun 14, 2025 to Feb 13, 2027
  3. Primary completion date: Jun 2023 to Jun 14, 2024 Completion date: Dec 2023 to Jun 14, 2025 · Eligibility criteria expanded, about 19 wordsv5 Show 2 more changesShow less
    • Completion date: Dec 2023 to Jun 14, 2025
    • Eligibility criteria expanded, about 19 words

    See this version in full on ClinicalTrials.gov ↗

  4. 3 versions Re-verified since Aug 12, 2021, no change to tracked fieldsv2-v4
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.
Trial Details
NCT Number NCT03600779
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Sclerosis, Multiple
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov